Lenvatinib Plus PD-1 Inhibitors as First-Line Treatment in Patients With Unresectable Biliary Tract Cancer: A Single-Arm, Open-Label, Phase II Study

Qiyi Zhang(Blood Center of Zhejiang Province), Sheng Yan(Blood Center of Zhejiang Province)
Frontiers in Oncology
November 24, 2021
Cited by 79


Related Papers